Drug Approval | February 21, 2023
Astellas updates on Fezolinetant application in US
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
Cipla has received 8 inspectional observations in Form 483
Sirolimus Tablets had annual sales of USD 69 million in the United States (IQVIA MAT Dec. 2022)
FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
The partnership is announced at Aero India 2023, Bangalore
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
Bosentan Tablets for Oral Suspension had annual sales of USD 16 mn in the United States (IQVIA MAT Dec. 2022)
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
Company's Unit - IX, an API intermediate facility situated at Sangareddy District, Telangana, has now been classified as Voluntary Action Indicated
Subscribe To Our Newsletter & Stay Updated
